Dose intensification with infliximab in patients with rheumatoid arthritis

Annals of Pharmacotherapy

Volumn 39, Issue 12, 2005, Pages 2021-2025

  Berger, Ariel ^a   Edelsberg, John ^a   Li, Tracy T ^b   Maclean, John R ^b   Oster, Gerry ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Drug utilization; Infliximab; Intravenous infusions; Rheumatoid arthritis; antirheumatic agents

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE;

ADULT; AGED; ARTICLE; CYTOKINE RELEASE; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DRUG UTILIZATION; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT INDICATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; FEMALE; HUMANS; INSURANCE, HEALTH; MALE; MIDDLE AGED;

EID: 28544434285     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G264     Document Type: Article

References (19)

1. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
2. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-46.
3. Infliximab. In: Physicians' desk reference. 59th ed. Montvale, NJ: Medical Economics Data, 2005:1117-22
4. Enbrel prescribing information. In: Physicians' desk reference. 59th ed. Montvale, NJ: Medical Economics Data, 2005:577-82.
5. Humira prescribing information. In: Physicians' desk reference. 59th ed. Montvale, NJ: Medical Economics Data, 2005:472-6.
6. Stern R, Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 2004;31:1538-45.
7. Sidiropoulos P, Bertsias G, Kritikos HD, Kouroumali H, Voudouris K, Boumpas DT, et al. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. Ann Rheum Dis 2004;63:144-8.
8. Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003;9(6 suppl):S136-43.
9. Fitzcharles MA, Clayton D, Menard HA. The use of infliximab in academic rheumatology practice: an audit of early clinical experience. J Rheumatol 2002;29:2525-30.
10. Billing guide for Remicade. Centocor. www.remicade.com/pdf/IN02032. pdf (accessed 2003 Apr 23).
11. Pasta DJ, Taylor JL, Henning JM. Probabilistic sensitivity analysis incorporating the bootstrap: an example comparing treatments for the eradication of Helicobacter pylori. Med Decis Making 1999;19:353-63.
12. SAS/STAT user's guide. Ver. 8.4th ed. Vols. 1-2. Cary, NC: SAS Institute, 1992.
13. US Department of Health and Human Services (DHHS), National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-1994, NHANES III Adult, Exam, and Laboratory Data Files (CD-ROM). Hyattsville, MD: Centers for Disease Control and Prevention: 1996. Public Use Data File Documentation 762000. Available from the National Technical Information Service (NTIS), Springfield, VA.
14. Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
15. Maini R, St. Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 1999;354:1932-9.
16. 2005 Drug topics red book. Montvale, NJ: Thomson PDR, 2005.
17. Jollis JG, Ancukiewicz M, DeLong ER, Pryor DB, Muhlbaier LH, Mark DB. Discordance of databases designed for claims payment versus clinical information systems. Ann Intern Med 1993;119:844-50.
18. Quam L, Ellis LB, Venus P, Clouse J, Taylor CG, Leatherman S. Using claims data for epidemiologic research: the concordance of claims-based criteria with the medical record and patient survey for identifying a hypertensive population. Med Care 1993;31:498-507.
19. Fisher ES, Whaley FS, Krushat WM, Malenka DJ, Fleming C, Baron JA, et al. The accuracy of Medicare's hospital claims data: progress has been made, but problems remain. Am J Public Health 1992;82:243-8.